Search

everythingexperts & clinicslearnfaqsresearchcommunity

for

Search:↓

In this pilot study, no significant differences were observed between memantine and placebo groups in young adults with Down syndrome on the primary memory outcomes, but some improvement was noted in a secondary measure.

This study reviewed data from three hospitals and found that alopecia after DRESS occurred more often in severe cases, but the rate of corticosteroid treatment did not significantly differ between patients with and without alopecia.

In this ongoing phase 3 study, ritlecitinib demonstrated sustained efficacy up to 24 months in patients aged 12 or older with alopecia areata, showing increased response rates with or without an initial loading dose and supporting its long-term use.

In this study, 2-deoxy D-glucose did not prevent the progression of alopecia areata or promote hair regrowth in a mouse model despite its efficacy in other autoimmune conditions.

In this prospective phase II clinical trial, researchers are investigating whether adding dutasteride to combined androgen blockade can improve the response rate and clinical outcomes for patients with androgen receptor-positive recurrent or metastatic salivary duct carcinoma.

In this study, researchers created a hydrogel that reduces oxidative stress and releases a pro-angiogenic drug in response to enzyme activity, which accelerated healing and improved tissue regeneration in chronic diabetic wounds during in vivo experiments.

This study found that ritlecitinib 50 mg offered a lower cost per responder than baricitinib 2 or 4 mg for treating severe alopecia areata at Weeks 24 and 52, potentially influencing reimbursement decisions.

The hydrogel dressings speed up healing and reduce scarring.

In this study, acellular dermal matrix hydrogels significantly improved healing in a rat model of radiation-induced skin injury by promoting angiogenesis and modulating inflammation, suggesting potential as a novel treatment for this common radiotherapy complication.

This study observed that most patients with alopecia areata experienced sustained scalp hair regrowth after 48 weeks of ritlecitinib treatment, with safety consistent with prior findings.

In this study, the authors identified the DHRS9 SNP rs72623193 as most significantly associated with response to dutasteride in treating male pattern hair loss, with additional variants potentially contributing.

This review discusses the use of Raman spectroscopy to evaluate drug penetration in alopecia treatments and suggests it may be a promising tool for enhancing the effectiveness of laser-assisted drug delivery.

In this study, participants receiving a 50-mg maintenance dose of ritlecitinib reported greater improvements in emotional and activity limitations due to hair loss by Week 48 compared to those on a 10-mg dose.

In this study, patients with treatment-refractory alopecia areata who received oral ritlecitinib 50 mg daily experienced significant hair regrowth, with 52.6% achieving complete scalp regrowth and improved Severity of Alopecia Tool scores, indicating its potential effectiveness in real-world settings.

Certain patient characteristics can help predict hair regrowth success with ritlecitinib in alopecia areata.

This study found that hair regrowth occurred in 72.2% of alopecia areata patients treated with diphencyprone, with disease extent at baseline and duration affecting outcomes.

This review suggests that the compound DRDE-07, originally a sulphur-mustard countermeasure candidate, could potentially be repurposed for skin protection due to its compatibility with pathways involved in oxidative stress and inflammation, though further experimental study is needed to confirm its therapeutic applicability in dermatology.

Daclizumab may cause psoriasis-like skin problems in multiple sclerosis patients.

This study identified common and unexpected adverse events associated with ritlecitinib in real-world use, providing insights into its safety profile for treating severe alopecia areata.

This paper reviews existing and emerging therapies for alopecia areata, describing the impact of targeted treatments in this field, and introduces a global network of disease registers to study the long-term safety and effectiveness of these new options.

This study reports that ritlecitinib, when used for up to 24 months in patients aged 12 and older with alopecia areata, has an acceptable safety profile, with a similar proportion of adverse events in both ritlecitinib and placebo groups in the placebo-controlled cohort.

This audit of ritlecitinib prescribing for severe alopecia areata found that regional practices largely followed national guidelines but highlighted the need for better psychological assessments and more consistent use of SALT scoring to inform treatment continuation decisions after 36 weeks.

This study found that activation of RORA significantly promotes the level of autophagy in rat hair follicle stem cells, suggesting a potential target for research on hair follicle development and treatments for conditions like alopecia.

This review examines experimental and clinical evidence on PDRN, a drug derived from salmon DNA that acts via the adenosine A2A receptor and shows promise for tissue repair and treatment of diabetic foot ulcers in regenerative medicine.

This narrative review found that ritlecitinib shows consistent effectiveness and a favorable safety profile for treating alopecia areata in clinical trials and real-world settings, with progressive hair regrowth observed, particularly when treatment is initiated early and maintained appropriately.

This review suggests that PDRN shows promise as a safe and versatile regenerative agent for wound healing and other dermatological applications, based on its dual mechanisms and clinical evidence of efficacy.

This study established an IRGDS model with diagnostic capability for alopecia areata, which may serve as an auxiliary marker for the condition.

In this study, researchers identified two novel peptidylarginine deiminases from treated rat keratinocytes, both showing enzyme activity with PAD‐R11 reflecting a characteristic of epidermal enzymes.

This study reports that ritlecitinib was prescribed to a diverse group of patients, including adolescents and adults with and without prior treatment for Alopecia Areata, in the first three months after FDA approval, potentially expanding care options for this condition.